

AD_____

GRANT NUMBER DAMD17-97-1-7124

TITLE: Protein-Engineered Radiometal Chelates for Immunotherapy
of Breast Cancer

PRINCIPAL INVESTIGATOR: Jefferson Foote, Ph.D.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center
Seattle, Washington 98104-1024

REPORT DATE: April 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Apr 97 - 31 Mar 98)	
4. TITLE AND SUBTITLE Protein-Engineered Radiometal Chelates for Immunotherapy of Breast Cancer			5. FUNDING NUMBERS DAMD17-97-1-7124	
6. AUTHOR(S) Jefferson Foote, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center Seattle, Washington 98104-1024			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)			19990318 068	
The objective of this project is to genetically engineer a radiometal binding site in a human antibody constant region, for eventual use in tumor radioimmunotherapy. Our initial design was based on molecular modeling and used a humanized antibody Fab fragment expressed in <i>E. coli</i>. The engineered binding site, consisting of 5 point mutations in the human Ck domain, destabilized the recombinant protein, leading to proteolysis. We have attempted to address this problem by using expedited isolation procedures, modifying the binding site design, and expressing the protein within protease-negative host strains.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Jefferson Foote 10 Aug 98
PI - Signature Date

Table of Contents

	Page
Front Cover	1
Report Documentation Page (SF 298)	2
Foreword	3
Table of Contents	4
Annual Progress Report	
Introduction	5
Body	5 - 6
Conclusions	6
References	6
Appendices	None

Introduction

The isotope Yttrium-90 has decay properties (β -emission, path length <1 cm in tissue) that would make it ideal for radioimmunotherapy. However, stable attachment of yttrium to antibodies that could target the isotope to a tumor have been problematical. The current best technology is to use a synthetic bifunctional chelator to bind the yttrium to the antibody. However, these synthetic molecules when bound to an immunoglobulin act as classical haptens, and can induce an immune response in patients. Such an immune response, directed to the radiopharmaceutical through the chelator, causes rapid inactivation and elimination of the administered therapeutic agent.

Our proposal was to genetically engineer an yttrium binding site in a constant domain of a human immunoglobulin. The site would be located away from the surface of the protein, and would be composed of charged amino acid side chains, rather than an exogenous organic molecule, hence would not be immunogenic.

At the start of the funding period we had engineered an antibody Fab fragment with a putative yttrium binding site in the human C κ domain, and had expressed it in *E. coli*. We had expected, and had found, that this protein would be very difficult to make, because of instability introduced by burying charged residues in the interior of a protein folding domain. Extensive proteolysis during expression suggested that the recombinant protein had difficulty folding. We had prepared approximately 1 mg of intact protein from a 20 L fermentor run. Our initial efforts to demonstrate yttrium binding were unsuccessful, and exhausted the initial supply of protein.

Body

We decided to attack the protein folding problem directly, using four strategies:

- Fine-tune Fab expression and isolation.
- Use protease-negative mutant host strains
- Redesign the yttrium binding site.
- Co-express genes that promote disulfide bond formation

Fine-tune Fab expression and isolation. Biochemical steps in the protein isolation procedure were extensively optimized, emphasizing speed, low temperature, and addition of EDTA and protease inhibitors. We exhaustively explored rapid isolation on affinity media, including peptostreptococcal protein L (1) and immobilized anti-human C κ monoclonal antibodies 141PF11 and HP6053 (2). These modifications improved recovery of intact protein from small-scale (50 ml) cultures, but could not successfully be applied on a fermentor scale.

Use protease-negative mutant host strains. We obtained several *E. coli* strains mutant in one or more of the protease genes *ompT*, *degP*, *clpP*, and *lon*. These strains are listed in Table I. Vector constructs carrying Fab with the engineered C κ sequence and a control with the wild-type sequence were transferred to the mutant strains, and the expression and rapid isolation procedures were applied. Surprisingly, use of the mutant strains gave no improved recovery of intact Fab.

Table I. Protease-negative E. coli host strains.

Strain	Relevant protease mutations	Reference
SA2817	ompT degP	(3)
SG22094	lon, clpP	(4)
UT5600	ompT	(5)

Redesign the yttrium binding site. Our designed metal binding site had 4 charged amino acid side chains placed with a cubic geometry at the heart of a kappa constant region domain. This charge density obviously would destabilize the domain, but our expectation was that metal chelation would lend some stability by partially neutralizing these charges. To reduce the thermodynamically unfavorable effect of burying charges in a hydrophobic protein domain, we redesigned the metal binding site to contain 2 charged residues. Sequence modifications tested are shown in Table II. However, two alternative designs failed to increase the yield of intact protein.

Table II. Mutated residues in the yttrium binding site designs tested.

Construct	115	136	144	146	196
Control (wild type Ck)	V	L	A	V	V
HuLys Y	E	D	E	E	A
HuLys Y2	E	L	E	V	A
HuLys Y3	E	L	E	V	S

Co-express genes that promote disulfide bond formation. Work by others has shown the importance of disulfide formation in folding of recombinant immunoglobulin fragments (6, 7). We are currently building into our expression vector the genes for 4 enzymes used for disulfide formation in the periplasm of E. coli. Our presumption is that increased gene product copy number will make protein folding more rapid, hence channel more recombinant Fab down this pathway, rather than a proteolytic pathway. At present we have acquired or cloned by PCR the genes listed in the table. Construction is in progress of a plasmid vector that contains all four genes with their endogenous control regions, as well as sequences for Fab expression. We do not yet have data on how this extra machinery will affect production of intact Fab.

Table III. Disulfide metabolism genes incorporated into expression construct.

Gene	Function	Reference
dsbA	Oxidize protein thiols to disulfides	(8)
dsbB	Regenerate (reduce) dsbA	(9)
dsbC	Disulfide isomerase	(10, 11)
dipZ	Maintain dsbC in reduced (thiol) form	(12, 11)

Conclusions

The major obstacle in this project is proteolytic degradation of recombinant Fab, due to the destabilizing effect of the engineered radiometal binding site. Building the binding site sequentially, one amino acid residue at a time, was not a successfully strategy for remediating this instability. Expedited procedures for biochemical isolation of recombinant Fab are necessary, but not sufficient, for adequate yields of protein. These methods must be accompanied by genetic modifications of the host strain and/or vector. Use of host strains with single or double protease mutations did not improve expression. A strain containing complete protease knockout (13) may be necessary.

References

1. Ståhl, S., Nygren, P.-Å., Sjölander, A. & Uhlén, M. (1993) Engineered bacterial receptors in immunology. *Curr. Opin Immunol.* 5, 272-277.
2. Reimer, C. B., Phillips, D. J., Aloisio, C. H., Moore, D. D., Galland, G. G., Wells, T. W., Black, C. M. & McDougal, J. S. (1984) Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. *Hybridoma* 3, 263-275.
3. Strauch, K. L., Johnson, K. & Beckwith, J. (1989) Characterization of degP, a gene required for proteolysis in the cell envelope and essential for growth of *Escherichia coli* at high temperature. *J. Bacteriol.* 171, 2689-2696.
4. Maurizi, M. R., Clark, W. P., Katayama, Y., Rudikoff, S., Pumphrey, J., Bowers, B. & Gottesman, S. (1990) Sequence and structure of Clp P, the proteolytic component of the ATP-dependent Clp protease of *Escherichia coli*. *J. Biol. Chem.* 265, 12536-12545.
5. Earhart, C. F., Lundrigan, M., Pickett, C. L. & Pierce, J. R. (1979) *Escherichia coli* K-12 mutants that lack major outer membrane protein a. *FEMS Microbiol. Lett.* 6, 277-280.
6. Glockshuber, R., Malia, M., Pfitzinger, I. & Plückthun, A. (1990) A comparison of strategies to stabilize immunoglobulin Fv fragments. *Biochemistry* 29, 1362-1367.
7. Wulfig, C. & Plückthun, A. (1994) Correctly folded T-cell receptor fragments in the periplasm of *Escherichia coli*. Influence of folding catalysts. *J. Mol. Biol.* 242, 655-669.
8. Bardwell, J. C., McGovern, K. & Beckwith, J. (1991) Identification of a protein required for disulfide bond formation in vivo. *Cell* 67, 581-589.
9. Missiakas, D., Georgopoulos, C. & Raina, S. (1993) Identification and characterization of the *Escherichia coli* gene dsbB, whose product is involved in the formation of disulfide bonds in vivo. *Proc. Natl. Acad. Sci. USA* 90, 7084-7088.
10. Missiakas, D., Georgopoulos, C. & Raina, S. (1994) The *Escherichia coli* dsbC (xprA) gene encodes a periplasmic protein involved in disulfide bond formation. *EMBO J.* 13, 2013-2020.
11. Rietsch, A., Belin, D., Martin, N. & Beckwith, J. (1996) An in vivo pathway for disulfide bond isomerization in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 93, 13048-13053.
12. Missiakas, D., Schwager, F. & Raina, S. (1995) Identification and characterization of a new disulfide isomerase-like protein (DsbD) in *Escherichia coli*. *EMBO J.* 14, 3415-3424.
13. Meerman, H. J. & Georgiou, G. (1994) Construction and characterization of a set of *E. coli* strains deficient in all known loci affecting the proteolytic stability of secreted recombinant proteins. *Bio/Technology* 12, 1107-1110.